Cabometyx

Active Ingredient(s): Cabozantinib (S)-Malate
FDA Approved: * April 25, 2016
Pharm Company: * EXELIXIS INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Cabometyx Overview

Cabozantinib, sold under the brand-name Cabometyx and Cometriq, is a medication used to treat medullary thyroid cancer and a second line treatment for renal cell carcinoma among others. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. It was discovered and developed by Exelixis Inc. In 2012 cabozantinib in its capsule formulation was approved by the U.S. FDA under the name Cometriq for treating patients with medullary thyroid cancer.&a...

Read more Cabometyx Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Cabozantinib

Recent Cabometyx Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Cabozantinib (S)-Malate
  • Capsule: 20mg, 80mg
  • Tablet: 20mg, 40mg, 60mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Cabometyx: (3 results)

Sorted by National Drug Code
  • 42388-023 Cabometyx 60 mg Oral Tablet by Exelixis, Inc.
  • 42388-024 Cabometyx 20 mg Oral Tablet by Exelixis, Inc.
  • 42388-025 Cabometyx 40 mg Oral Tablet by Exelixis, Inc.

Other drugs which contain Cabozantinib (S)-Malate or a similar ingredient: (2 results)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 18 December 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA